Sabby Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Sabby Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-110,000	Closed	-$1.73M	–	333
2016 Q4	$1.69M	Sell	110,000 -65,000	-37%	-$844K	0.1%	116
2016 Q3	$2.28M	Sell	175,000 -130,964	-43%	-$1.74M	0.09%	118
2016 Q2	$4.26M	Buy	305,964 +113,642	+59%	+$1.67M	0.22%	59
2016 Q1	$2.92M	Buy	192,322 +69,709	+57%	+$1.07M	0.15%	69
2015 Q4	$2.33M	Buy	122,613 +5,567	+5%	+$106K	0.13%	110
2015 Q3	$2.22M	Buy	117,046 +61,433	+110%	+$1.53M	0.09%	145
2015 Q2	$1.43M	Buy	+55,613	New	+$1.58M	0.05%	199
2014 Q1	–	Sell	-23,444	Closed	-$945K	–	278
2013 Q4	$945K	Buy	23,444 +8,986	+62%	+$382K	0.06%	126
2013 Q3	$552K	Sell	14,458 -2,378	-14%	-$85.1K	0.04%	152
2013 Q2	$610K	Buy	+16,836	New	+$721K	0.04%	137

Other funds holding PRTK

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Sabby Management's PRTK Position: Q1 2017 in Review

Sabby Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2017, closing a stake of 110,000 shares — an estimated $1.73M sold.

Sabby Management first reported a position in PRTK in Q2 2013 and held it in 10 quarters. The position peaked at $4.26M in Q2 2016. 103 funds tracked by Wall St. Rank hold PRTK as of Q1 2017.

Sabby Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Sabby Management sold 110,000 Paratek Pharmaceuticals, Inc. shares in Q1 2017, an estimated $1.73M.
Sabby Management first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 10 quarters.
Sabby Management's Paratek Pharmaceuticals, Inc. position peaked at $4.26M in Q2 2016.
103 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2017.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.